Publications by authors named "T E Lad"
Background: Patient navigation (PN) is a promising yet underused approach to address Hispanic/Latino (H/L) cancer survivors' unmet supportive care needs. The authors conducted a randomized trial to evaluate the effect of a culturally tailored PN program with the LIVESTRONG Foundation's Cancer Navigation Services (PN-LCNS) on reducing unmet needs in H/L survivors.
Methods: From 2012 to 2015 at two US sites, 288 H/L survivors diagnosed with breast, prostate, or colorectal cancer were randomized to a PN-LCNS program or to standard PN.
Article Synopsis
- The NRG/RTOG 0436 study investigated whether adding cetuximab to chemoradiation for non-operative esophageal cancer would improve patient-reported outcomes (PROs), focusing on the FACT-Esophageal cancer subscale (ECS).
- The study was stopped early due to failing to meet overall survival (OS) targets; among 344 enrolled patients, those receiving CRT plus cetuximab showed less improvement in ECS compared to those receiving standard CRT alone (37% vs. 53%).
- Overall, the results indicated that adding cetuximab did not enhance PROs related to symptoms, swallowing, or eating, and there was no significant link between clinical complete
Purpose: The aim of this study was to characterize the prevalence of cardiometabolic comorbidities (i.e., diabetes, peripheral vascular disease, myocardial infarction, congestive heart failure, cerebrovascular disease) among Hispanic/Latino cancer survivors and examine the impact of cardiometabolic comorbidities on health-related quality of life (HRQoL), unmet supportive care needs, patient-provider communication self-efficacy, satisfaction with cancer care, and increases in healthy behaviors.
View Article and Find Full Text PDFPurpose: Primary prophylactic granulocyte colony-stimulating factors (PP-CSFs) are prescribed alongside chemotherapy regimens that carry a significant risk of febrile neutropenia (FN). As part of S1415CD, a prospective, pragmatic trial evaluating the impact of automated orders to improve PP-CSF prescribing, we evaluated patients' baseline knowledge of PP-CSF and whether that knowledge improved following the first cycle of chemotherapy.
Methods: Adult patients with breast, colorectal, or non-small-cell lung cancer initiating chemotherapy were enrolled in S1415CD between January 2016 and April 2020.